Trial Outcomes & Findings for Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy (NCT NCT05152927)
NCT ID: NCT05152927
Last Updated: 2025-12-15
Results Overview
Median number of frozen sections (or aspirate) sent for analysis during the parathyroidectomy (PTx) procedure to confirm potential parathyroid tissue
COMPLETED
NA
79 participants
At the end of the parathyroidectomy, up to 5 hours
2025-12-15
Participant Flow
Participant milestones
| Measure |
Parathyroid Eye (PTeye)
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Overall Study
STARTED
|
38
|
41
|
|
Overall Study
COMPLETED
|
38
|
41
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy
Baseline characteristics by cohort
| Measure |
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
Total
n=79 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
68 years
n=9 Participants
|
64 years
n=32 Participants
|
67 years
n=18 Participants
|
|
Sex: Female, Male
Female
|
27 Participants
n=9 Participants
|
30 Participants
n=32 Participants
|
57 Participants
n=18 Participants
|
|
Sex: Female, Male
Male
|
11 Participants
n=9 Participants
|
11 Participants
n=32 Participants
|
22 Participants
n=18 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=9 Participants
|
4 Participants
n=32 Participants
|
5 Participants
n=18 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
37 Participants
n=9 Participants
|
36 Participants
n=32 Participants
|
73 Participants
n=18 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=9 Participants
|
1 Participants
n=32 Participants
|
1 Participants
n=18 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=9 Participants
|
0 Participants
n=32 Participants
|
0 Participants
n=18 Participants
|
|
Race (NIH/OMB)
Asian
|
4 Participants
n=9 Participants
|
3 Participants
n=32 Participants
|
7 Participants
n=18 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
1 Participants
n=9 Participants
|
1 Participants
n=32 Participants
|
2 Participants
n=18 Participants
|
|
Race (NIH/OMB)
Black or African American
|
2 Participants
n=9 Participants
|
2 Participants
n=32 Participants
|
4 Participants
n=18 Participants
|
|
Race (NIH/OMB)
White
|
27 Participants
n=9 Participants
|
27 Participants
n=32 Participants
|
54 Participants
n=18 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=9 Participants
|
0 Participants
n=32 Participants
|
0 Participants
n=18 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
4 Participants
n=9 Participants
|
8 Participants
n=32 Participants
|
12 Participants
n=18 Participants
|
|
Region of Enrollment
United States
|
38 participants
n=9 Participants
|
41 participants
n=32 Participants
|
79 participants
n=18 Participants
|
PRIMARY outcome
Timeframe: At the end of the parathyroidectomy, up to 5 hoursMedian number of frozen sections (or aspirate) sent for analysis during the parathyroidectomy (PTx) procedure to confirm potential parathyroid tissue
Outcome measures
| Measure |
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Median Number of Frozen Sections (or Parathyroid Aspirate) Sent for Analysis
|
0 frozen aspirate samples
Interval 0.0 to 1.0
|
0 frozen aspirate samples
Interval 0.0 to 1.0
|
SECONDARY outcome
Timeframe: 5-14 days after PTx procedureFailure of intra-operative parathyroid hormone (PTH) to normalize (defined as failure of PTH to drop \> 50% of its baseline value at final intra-operative PTH assay and/or failure of PTH to drop \< 65 pg/ml or 6.9 pmol/L). Participants will be categorized as having persistent hyperparathyroidism (Immediate) Yes or No.
Outcome measures
| Measure |
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Number of Participants With Persistent Hyperparathyroidism (Immediate)
|
0 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: 5-14 days after PTx procedurePopulation: Participants from both groups were missing labs. Not all PTEye participants returned to the clinic for blood draws within 5-14 days to obtain lab values required to calculate this endpoint and standard clinical care does not necessitate participants returning for labs routinely at each follow-up time points.
Elevated blood calcium levels (total blood calcium level \> 10.5 mg/dL or 2.6 mmol/L) with/without elevated parathyroid hormone (PTH) (serum intact PTH \> 65 pg/ml or 6.9 pmol/L) at first postoperative visit. Participants will be categorized as having persistent hyperparathyroidism or hypercalcemia (transient) Yes or No.
Outcome measures
| Measure |
Parathyroid Eye (PTeye)
n=21 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=20 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Number of Participants With Persistent Hyperparathyroidism or Hypercalcemia (Transient)
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Up to 6 months after PTx procedurePopulation: Participants from both groups were missing labs. Not all PTEye participants returned to the clinic for blood draws within 5-14 days to obtain lab values required to calculate this endpoint and standard clinical care does not necessitate participants returning for labs routinely at each follow-up time points.
If blood calcium with/without parathyroid hormone (PTH) has not normalized at 1st post-operative visit, calcium and/or PTH is subsequently measured as necessary. Patient is defined to have a failed parathyroidectomy if hypercalcemia/hyperparathyroidism (defined as total blood calcium level \> 10.5 mg/dL or 2.6 mmol/L, with/without elevated serum intact PTH \> 65 pg/ml or 6.9 pmol/L) persists at or after the 6th postoperative month. Participants will be categorized has having persistent hyperparathyroidism or hypercalcemia (failed parathyroidectomy), Yes or No.
Outcome measures
| Measure |
Parathyroid Eye (PTeye)
n=29 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=33 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Number of Participants Persistent Hyperparathyroidism or Hypercalcemia (Failed Parathyroidectomy)
|
0 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: At the end of the parathyroidectomy, up to 5 hoursOverall number of parathyroid glands identified (Combined both the experimental Group (Glands identified with naked eye + NIRAF) and Control Group (Glands identified with naked eye)
Outcome measures
| Measure |
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Number of Parathyroid Glands (PG) Identified
|
45 parathyroid glands
|
45 parathyroid glands
|
SECONDARY outcome
Timeframe: At the end of the parathyroidectomy, up to 5 hoursPopulation: Only 4 participants had glands identified with NIRAF, which was not seen with surgeon's naked eye
Median number of parathyroid glands identified with NIRAF, which was not seen with surgeon's naked eye during bilateral neck explorations (where the surgeon is looking for more than 1 parathyroid gland)
Outcome measures
| Measure |
Parathyroid Eye (PTeye)
n=4 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Median Number of Parathyroid Glands Identified With NIRAF (PTeye Group Only)
|
1 parathyroid glands
Interval 1.0 to 2.0
|
—
|
SECONDARY outcome
Timeframe: At the end of the parathyroidectomy, up to 5 hoursMedian number of diseased parathyroid glands identified intra-operatively versus glands localized preoperatively using sestamibi, Computerized tomography (CT) or ultrasound
Outcome measures
| Measure |
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Median Number of Diseased Parathyroid Glands Identified Versus Preoperatively Localized Glands
Intra-operatively
|
1 parathyroid glands
Interval 1.0 to 2.0
|
1 parathyroid glands
Interval 0.0 to 2.0
|
|
Median Number of Diseased Parathyroid Glands Identified Versus Preoperatively Localized Glands
Localized pre-operatively
|
1 parathyroid glands
Interval 1.0 to 3.0
|
1 parathyroid glands
Interval 1.0 to 3.0
|
SECONDARY outcome
Timeframe: At the end of the parathyroidectomy, up to 5 hoursThe median number of intra-operative parathyroid hormone assays (per person) sent during the procedure to the lab
Outcome measures
| Measure |
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Median Number of Intra-operative Parathyroid Hormone (PTH) Assays Sent
|
5 assays
Interval 4.0 to 8.0
|
5 assays
Interval 4.0 to 12.0
|
SECONDARY outcome
Timeframe: During parathyroidectomy, up to 5 hoursPopulation: Data was not collected for one participant from each group
Median duration in minutes taken to identify 1st parathyroid gland in PTx procedure - timed from skin incision to finding PG
Outcome measures
| Measure |
Parathyroid Eye (PTeye)
n=37 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=40 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Median Duration Taken to Identify First Parathyroid Gland
|
38 minutes
Interval 15.0 to 154.0
|
31 minutes
Interval 11.0 to 184.0
|
SECONDARY outcome
Timeframe: At the end of the parathyroidectomy, up to 5 hoursPopulation: Data was not collected for one participant from each group
Median duration taken to identify last parathyroid gland in PTx procedure - timed from skin incision to finding the last PG
Outcome measures
| Measure |
Parathyroid Eye (PTeye)
n=37 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=40 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Median Duration Taken to Identify Last Parathyroid Gland
|
48 minutes
Interval 16.0 to 224.0
|
35 minutes
Interval 11.0 to 184.0
|
SECONDARY outcome
Timeframe: Up to 5 hoursMedian duration of PTx procedure - timed from skin incision until the surgeon notifies the anesthesia team to awaken the patient in minutes
Outcome measures
| Measure |
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Median Duration of Parathyroidectomy (PTx) Procedure
|
87 minutes
Interval 34.0 to 243.0
|
82 minutes
Interval 26.0 to 296.0
|
SECONDARY outcome
Timeframe: At the end of the parathyroidectomy, up to 5 hoursMedian time in minutes taken for PTH to attain cure criteria or normalize - timed from skin incision until the PTH levels drops \> 50% of its baseline value and/or PTH drops \< 65 pg/ml or 6.9 pmol/L
Outcome measures
| Measure |
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Median Duration for Intraoperative Parathyroid Hormone (PTH) to Normalize
|
76 minutes
Interval 27.0 to 243.0
|
66 minutes
Interval 38.0 to 150.0
|
SECONDARY outcome
Timeframe: 0-72 hours after PTx procedureMedian number of nights spent in the hospital post-surgery is defined as having spent \<= 23 hours (0 nights) or \> 23 hours (1 night) at the hospital for postoperative recovery after the surgical procedure. Participants who had surgery scheduled for later in the day will be counted as spending one night in the hospital due to the minimum required observation period post-surgery and followed institutional standards for discharge; discharged the next day. Participants who had surgery scheduled for earlier in the day were discharged on the same day of surgery.
Outcome measures
| Measure |
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=40 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Median Number of Nights in the Hospital After Parathyroidectomy
<= 23 hours
|
0 number of nights
Interval 0.0 to 0.0
|
0 number of nights
Interval 0.0 to 0.0
|
|
Median Number of Nights in the Hospital After Parathyroidectomy
> 23 hours
|
1 number of nights
Interval 1.0 to 1.0
|
1 number of nights
Interval 1.0 to 1.0
|
SECONDARY outcome
Timeframe: Up to 10 days after PTx procedureThe median number of tissues per person that were excised by surgeon assumed to be parathyroid tissue, but is later validated as non-parathyroid tissue (false positive) by histology
Outcome measures
| Measure |
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Median Number of 'False Positive' Tissue Samples Excised by Surgeon
|
0 tissue samples
Interval 0.0 to 0.0
|
0 tissue samples
Interval 0.0 to 0.0
|
SECONDARY outcome
Timeframe: Up to 6 months after PTx procedureNumber of participants who required a doctor visit/emergency department visit and/or hospital admission due to persistent hypercalcemia and/or associated symptoms after the parathyroidectomy procedure will be categorized as binary (yes or no) if any follow-up visits or admissions occurred.
Outcome measures
| Measure |
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Number of Participants With Reported Doctor Visits/Emergency Department Visits or Hospital Admissions
|
5 participants
|
8 participants
|
SECONDARY outcome
Timeframe: From 6 - 12 months after PTx procedureNumber of participants with an indication that repeat PTx procedure may need to be performed after the current procedure will be categorized as binary (yes or no)
Outcome measures
| Measure |
Parathyroid Eye (PTeye)
n=38 Participants
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=41 Participants
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Number of Participants Who Have Had Repeat Parathyroidectomy (PTx) Procedure
|
0 Participants
|
1 Participants
|
Adverse Events
Parathyroid Eye (PTeye)
Usual Standard of Care
Serious adverse events
| Measure |
Parathyroid Eye (PTeye)
n=38 participants at risk
For participants assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
|
Usual Standard of Care
n=41 participants at risk
The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
|
|---|---|---|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
2.6%
1/38 • Number of events 1 • Up to 6 months
|
0.00%
0/41 • Up to 6 months
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify
|
0.00%
0/38 • Up to 6 months
|
2.4%
1/41 • Number of events 1 • Up to 6 months
|
|
Injury, poisoning and procedural complications
Fracture
|
0.00%
0/38 • Up to 6 months
|
2.4%
1/41 • Number of events 1 • Up to 6 months
|
|
Cardiac disorders
Pericardial effusion
|
0.00%
0/38 • Up to 6 months
|
2.4%
1/41 • Number of events 1 • Up to 6 months
|
|
Nervous system disorders
Syncope
|
0.00%
0/38 • Up to 6 months
|
2.4%
1/41 • Number of events 1 • Up to 6 months
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified (incl cysts and polyps), Other - specify
|
0.00%
0/38 • Up to 6 months
|
2.4%
1/41 • Number of events 1 • Up to 6 months
|
Other adverse events
Adverse event data not reported
Additional Information
Dr. Quan-Yang Duh, MD
University of California, San Francisco
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place